Tradestie Institutional Equity Comparison Engine
SVRA vs SANA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SVRA Overall Edge
SVRA Captures Institutional Edge (3โ1 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Savara Inc. (SVRA) driven by superior Valuation, Momentum & Technical, Options & Structure while SANA counters with relative strength in Growth & Margin. Fundamentally, SVRA trades at 0.4x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SANA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SVRA sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
SVRA
SVRA 0.4x vs SANA N/M Fwd P/E
Growth & Margin Winner
SANA
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
SVRA
1Y +4.8% vs -48.6% ยท 52W Pos 15% vs 1%
Options & Structure Winner
SVRA
BREAKDOWN (17th %ile IV) vs BREAKDOWN (4th %ile IV)
SVRA
NASDAQ
Savara Inc.
Pharmaceutical Preparations
$4.46
-3.77% 1D
Market Cap
$1.0B
1M Return
+0.34%
1Y Return
+4.81%
Forward P/E
0.4x
Unified AI Score
55.6 / 100
HOLD
Tech 30.0
Fund 54.0
Flow 70.0
Mom 54.0
SANA
NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap
$605.3M
1M Return
-17.18%
1Y Return
-48.63%
Forward P/E
N/M
Unified AI Score
44.3 / 100
HOLD
Tech 33.0
Fund 51.0
Flow 66.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SVRA +4.81%
SANA -48.63%
Spread: +53.44 pp (SVRA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SVRA TTM Op. Margin: 0.0%
SANA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SVRA vs SANA. Trailing 12-month operating profitability (SVRA 0.0% vs SANA 0.0%) and valuation multiples (SVRA 0.4x vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SVRA | SANA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.0B | $605.3M | Larger Scale | SVRA |
| Trailing P/E Ratio Valuation | 0.4x | N/M | Lower Multiple | SVRA |
| Forward P/E Ratio Valuation | 0.4x | N/M | Lower Multiple | SVRA |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -151.0% | -79.5% | Higher ROE | SANA |
| 52-Week Range Position Momentum | 15% ($4โ$7) | 1% ($2โ$5) | Stronger Trend | SVRA |
| Beta / 30D Volatility Risk Regime | 1.47ฮฒ ยท 73% Vol | 1.82ฮฒ ยท 78% Vol | Lower Realized Risk | SVRA |
| Unified Institutional Score Composite Signal | 55.6 / 100 (HOLD) | 44.3 / 100 (HOLD) | Higher Composite | SVRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SVRA vs SANA Buy Guide
SVRA
BREAKDOWN
92d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
17th %ile
IV Regime
Compressed (<25th %ile)
SANA
BREAKDOWN
57d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
4th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SVRA nor SANA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.